| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4241339
Max Phase: Preclinical
Molecular Formula: C24H26N6O2
Molecular Weight: 430.51
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: Cn1ccc(-c2ccc(Cc3cc(C(=O)NC[C@@H]4CCCO4)nc4c3ccn4C)cn2)n1
Standard InChI: InChI=1S/C24H26N6O2/c1-29-9-7-19-17(12-16-5-6-20(25-14-16)21-8-10-30(2)28-21)13-22(27-23(19)29)24(31)26-15-18-4-3-11-32-18/h5-10,13-14,18H,3-4,11-12,15H2,1-2H3,(H,26,31)/t18-/m0/s1
Standard InChI Key: FGEROXCEFCKHLR-SFHVURJKSA-N
Associated Targets(non-human)
Muscarinic acetylcholine receptor M1 3437 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 430.51 | Molecular Weight (Monoisotopic): 430.2117 | AlogP: 2.87 | #Rotatable Bonds: 6 |
| Polar Surface Area: 86.86 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 1.84 | CX LogP: 3.05 | CX LogD: 3.05 |
| Aromatic Rings: 4 | Heavy Atoms: 32 | QED Weighted: 0.51 | Np Likeness Score: -1.04 |
References
| 1. Engers JL, Childress ES, Long MF, Capstick RA, Luscombe VB, Cho HP, Dickerson JW, Rook JM, Blobaum AL, Niswender CM, Engers DW, Conn PJ, Lindsley CW.. (2018) VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events., 9 (9): [PMID:30258541] [10.1021/acsmedchemlett.8b00261] |
Source
Source(1):